With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.